Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
TENX · Why this verdict
Why Tenax Therapeutics (TENX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Tenax Therapeutics offers a favorable risk/reward setup and a perfect earnings beat streak, but the underlying fundamentals remain weak and the large analyst upside estimate rests on thin, light coverage.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Tenax shows a strong risk/reward setup with an asymmetry ratio of 6.04 and 90.6% upside, an edge the engine attributes to the stock being a small cap below institutional reach at a $0.4B market cap. Edge rationale | The asymmetry ratio should stay above 1.5 as the stock's price converges toward its analyst target over 12 months. | →Stable |
| CounterBeing below institutional reach limits the pool of buyers who could drive a re-rating, so the favorable math may persist without ever being realized in price. | ||
Tenax has beaten earnings estimates in all of the last 4 quarters with an average surprise of 31.07%. Catalyst breakdown | The beat streak should continue into subsequent quarters with a positive surprise percentage, once a next earnings date is scheduled. | →Stable |
| CounterA small biotech with light analyst coverage can post beats against very low bars, which doesn't necessarily reflect operational strength. | ||
Despite the earnings beats, the company is cash-burning with a weak Piotroski F-Score of 2 out of 9 and no competitive moat, reflecting fragile core fundamentals. Quality breakdown | The Piotroski F-Score should climb to 4 or higher over the next 12 months as the fundamental picture improves. | →Stable |
| CounterEarly-stage biotech businesses are commonly cash-burning by design while funding clinical trials, so a low Piotroski score alone may not indicate distress. | ||
Analysts see 119% upside, but the signal is dampened by light coverage, meaning the number rests on few analyst estimates. Sentiment breakdown | Analyst coverage should broaden with multiple additional analysts initiating coverage to validate the 119% upside estimate over the next 12 months. | →Stable |
| CounterLight coverage can also mean the stock is under-followed and mispriced, so the dampened signal doesn't necessarily make the upside estimate less reliable. | ||
Tenax shows a strong risk/reward setup with an asymmetry ratio of 6.04 and 90.6% upside, an edge the engine attributes to the stock being a small cap below institutional reach at a $0.4B market cap.
→StableEdge rationale
- Expectation
- The asymmetry ratio should stay above 1.5 as the stock's price converges toward its analyst target over 12 months.
CounterBeing below institutional reach limits the pool of buyers who could drive a re-rating, so the favorable math may persist without ever being realized in price.
Tenax has beaten earnings estimates in all of the last 4 quarters with an average surprise of 31.07%.
→StableCatalyst breakdown
- Expectation
- The beat streak should continue into subsequent quarters with a positive surprise percentage, once a next earnings date is scheduled.
CounterA small biotech with light analyst coverage can post beats against very low bars, which doesn't necessarily reflect operational strength.
Despite the earnings beats, the company is cash-burning with a weak Piotroski F-Score of 2 out of 9 and no competitive moat, reflecting fragile core fundamentals.
→StableQuality breakdown
- Expectation
- The Piotroski F-Score should climb to 4 or higher over the next 12 months as the fundamental picture improves.
CounterEarly-stage biotech businesses are commonly cash-burning by design while funding clinical trials, so a low Piotroski score alone may not indicate distress.
Analysts see 119% upside, but the signal is dampened by light coverage, meaning the number rests on few analyst estimates.
→StableSentiment breakdown
- Expectation
- Analyst coverage should broaden with multiple additional analysts initiating coverage to validate the 119% upside estimate over the next 12 months.
CounterLight coverage can also mean the stock is under-followed and mispriced, so the dampened signal doesn't necessarily make the upside estimate less reliable.
Per-dimension breakdown
Quality
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.8 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 2.1 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.3 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.9 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 119%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 2.6 |
| growth rank | 5.0 |
Technical
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.8 |
| support resistance | 4.7 |
| 52w position | 6.3 |
| gap | 6.0 |
Risk (lower is worse)
5.9/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 6.6 |
| days to cover | 9.5 |
| volatility | 0.0 |
| beta | 7.5 |
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
8.3/10data confidence 75%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| surprise avg | 10.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- ASYMMETRY:6.0>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.5<4.5
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
6.05
Upside
+90.7%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.4B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.5<4.5 outcome against Value at 9.0 and asymmetric R:R of 6.05.
The strongest dimensions are Value at 9.0, Catalyst at 8.3, and Sentiment at 7.8; the weakest are Quality at 1.2, Momentum at 3.5, and Peer rank at 4.4. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 6.05 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Asymmetry Small Cap Edge
Trip ifAsymmetry ratio falls below 1.5 or upside narrows below 20%.
- P2Perfect Earnings Beat Streak
Trip ifCompany posts a miss with surprise below 0% at its next scheduled earnings report.
- P3Weak Fundamentals Cash Burn
Trip ifPiotroski F-Score rises above 5 out of 9 or free cash flow turns positive.
- P4Analyst Upside Light Coverage
Trip ifAnalyst upside estimate falls below 20% once coverage broadens beyond 8 ratings.